Michael Charlton to RNA, Viral
This is a "connection" page, showing publications Michael Charlton has written about RNA, Viral.
Connection Strength
1.334
-
Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
Score: 0.182
-
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
Score: 0.134
-
Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
Score: 0.129
-
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
Score: 0.126
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
Score: 0.115
-
The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
Score: 0.108
-
Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
Score: 0.095
-
Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
Score: 0.063
-
Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003 Nov; 9(11):S58-62.
Score: 0.054
-
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
Score: 0.048
-
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
Score: 0.044
-
Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol. 2000 Mar; 13(3):229-37.
Score: 0.042
-
Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
Score: 0.038
-
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
Score: 0.034
-
Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
Score: 0.031
-
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
Score: 0.026
-
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
Score: 0.024
-
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
Score: 0.024
-
Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999 Apr; 29(4):1220-6.
Score: 0.010
-
The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
Score: 0.010